Setting the target for pemphigus vulgaris therapy.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  JCI Insight

• Publication date

  2017-03-09

• Fields of study

  Medicine

• Identifiers
  DOI 10.1172/jci.insight.92021PMID 28289723PMCID PMC5333961
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia

  2017cited by this paper
• Structural basis of adhesive binding by desmocollins and desmogleins

  2016cited by this paper
• Monopathogenic vs multipathogenic explanations of pemphigus pathophysiology

  2016cited by this paper
• Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies

  2016influential reference
• Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease

  2016cited by this paper
• Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor.

  2016cited by this paper
• Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

  2016cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• 4-1BB Costimulation Ameliorates T Cell Exhaustion Induced by Tonic Signaling of Chimeric Antigen Receptors

  2015cited by this paper
• Critical Role of the Neonatal Fc Receptor (FcRn) in the Pathogenic Action of Antimitochondrial Autoantibodies Synergizing with Anti-desmoglein Autoantibodies in Pemphigus Vulgaris*

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Specific immunoadsorption of pathogenic autoantibodies in pemphigus requires the entire ectodomains of desmogleins

  2014cited by this paper
• Opportunistic infections in patients with pemphigus.

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Shared VH1-46 gene usage by pemphigus vulgaris autoantibodies indicates common humoral immune responses among patients

  2014cited by this paper
• Fibrinogen Reduction and Bleeding Complications in Plasma Exchange, Immunoadsorption and a Combination of the Two

  2014cited by this paper
• Persistence of Anti-Desmoglein 3 IgG+ B-Cell Clones in Pemphigus Patients Over Years

  2014cited by this paper
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014cited by this paper
• MAPKAP kinase 2 (MK2)-dependent and independent models of blister formation in pemphigus vulgaris

  2013cited by this paper
• Peptide-mediated desmoglein 3 crosslinking prevents pemphigus vulgaris autoantibody-induced skin blistering.

  2013cited by this paper
• Antigen-Specific Tolerance by Autologous Myelin Peptide–Coupled Cells: A Phase 1 Trial in Multiple Sclerosis

  2013cited by this paper
• Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response

  2013cited by this paper
• Signaling Dependent and Independent Mechanisms in Pemphigus Vulgaris Blister Formation

  2012cited by this paper
• Epitope spreading is rarely found in pemphigus vulgaris by large-scale longitudinal study using desmoglein 2-based swapped molecules.

  2012cited by this paper
• Population-specific association between a polymorphic variant in ST18, encoding a pro-apoptotic molecule, and pemphigus vulgaris.

  2012cited by this paper
• Adjuvant rituximab therapy of pemphigus: a single-center experience with 31 patients.

  2012cited by this paper
• Pemphigus autoantibodies generated through somatic mutations target the desmoglein-3 cis-interface.

  2012cited by this paper
• Enrichment of total serum IgG4 in patients with pemphigus

  2012cited by this paper
• Venom immunotherapy for preventing allergic reactions to insect stings.

  2012cited by this paper
• IgG‐induced clustering of desmogleins 1 and 3 in skin of patients with pemphigus fits with the desmoglein nonassembly depletion hypothesis

  2011cited by this paper
• Aire-dependent thymic expression of desmoglein 3, the autoantigen in pemphigus vulgaris, and its role in T-cell tolerance.

  2011cited by this paper
• Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.

  2011cited by this paper
• A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus.

  2011cited by this paper
• CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

  2011influential reference
• Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID)

  2011cited by this paper
• Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies.

  2011cited by this paper
• p38 MAPK Activation Is Downstream of the Loss of Intercellular Adhesion in Pemphigus Vulgaris*

  2010cited by this paper
• Novel ELISA systems for antibodies to desmoglein 1 and 3: correlation of disease activity with serum autoantibody levels in individual pemphigus patients

  2010cited by this paper
• Pathogenic anti-desmoglein MAbs show variable ELISA activity because of preferential binding of mature versus proprotein isoforms of desmoglein 3.

  2009cited by this paper
• B Cell Antigen Receptor Endocytosis and Antigen Presentation to T Cells Require Vav and Dynamin

  2009cited by this paper
• Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.

  2009influential reference
• Disruption of desmosome assembly by monovalent human pemphigus vulgaris monoclonal antibodies.

  2009cited by this paper
• Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses.

  2009cited by this paper
• Peptides Targeting the Desmoglein 3 Adhesive Interface Prevent Autoantibody-induced Acantholysis in Pemphigus*

  2009cited by this paper
• Pemphigus Vulgaris IgG Directly Inhibit Desmoglein 3-Mediated Transinteraction1

  2008cited by this paper
• Fcgamma receptors as regulators of immune responses.

  2008cited by this paper
• Rituximab exerts a dual effect in pemphigus vulgaris.

  2008cited by this paper
• Isolation of pathogenic monoclonal anti-desmoglein 1 human antibodies by phage display of pemphigus foliaceus autoantibodies.

  2008cited by this paper
• B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses.

  2008cited by this paper
• Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity.

  2008cited by this paper
• Bullous pemphigoid and pemphigus vulgaris—incidence and mortality in the UK: population based cohort study

  2008cited by this paper
• Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.

  2008cited by this paper
• Fcγ receptors as regulators of immune responses

  2008cited by this paper
• Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease

  2007cited by this paper
• Targeting pemphigus autoantibodies through their heavy-chain variable region genes.

  2007cited by this paper
• Dissecting the Anti-Desmoglein Autoreactive B Cell Repertoire in Pemphigus Vulgaris Patients1

  2007cited by this paper
• Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.

  2006cited by this paper
• p38MAPK inhibition prevents disease in pemphigus vulgaris mice

  2006cited by this paper
• Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin.

  2006cited by this paper
• Pathogenic human monoclonal antibody against desmoglein 3.

  2006cited by this paper
• Genetic and functional characterization of human pemphigus vulgaris monoclonal autoantibodies isolated by phage display.

  2005cited by this paper
• T-cell receptor triggering is critically dependent on the dimensions of its peptide-MHC ligand

  2005cited by this paper
• T Cell Recognition of Desmoglein 3 Peptides in Patients with Pemphigus Vulgaris and Healthy Individuals1

  2004cited by this paper
• Elucidation of eukaryotic elongation factor-2 contact sites within the catalytic domain of Pseudomonas aeruginosa exotoxin A.

  2004cited by this paper
• Type I Regulatory T Cells Specific for Desmoglein 3 Are More Frequently Detected in Healthy Individuals than in Patients with Pemphigus Vulgaris1

  2004cited by this paper
• Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases.

  2003cited by this paper
• Dichotomy of Autoreactive Th1 and Th2 Cell Responses to Desmoglein 3 in Patients with Pemphigus Vulgaris (PV) and Healthy Carriers of PV-Associated HLA Class II Alleles1

  2003cited by this paper
• Induction of Pemphigus Phenotype by a Mouse Monoclonal Antibody Against the Amino-Terminal Adhesive Interface of Desmoglein 3 1

  2003cited by this paper
• C-Cadherin Ectodomain Structure and Implications for Cell Adhesion Mechanisms

  2002cited by this paper
• IgG4 breaking the rules

  2002cited by this paper
• Predominant IgG4 subclass in autoantibodies of pemphigus vulgaris and foliaceus.

  2001cited by this paper
• The use of plasmapheresis and immunosuppression in the treatment of pemphigus vulgaris.

  2000cited by this paper
• Development of chimeric molecules for recognition and targeting of antigen‐specific B cells in pemphigus vulgaris

  2000cited by this paper
• Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production.

  2000cited by this paper
• Pemphigus vulgaris-IgG causes a rapid depletion of desmoglein 3 (Dsg3) from the Triton X-100 soluble pools, leading to the formation of Dsg3-depleted desmosomes in a human squamous carcinoma cell line, DJM-1 cells.

  1999cited by this paper
• The KDEL retrieval system is exploited by Pseudomonas exotoxin A, but not by Shiga-like toxin-1, during retrograde transport from the Golgi complex to the endoplasmic reticulum.

  1999cited by this paper
• Usefulness of enzyme‐linked immunosorbent assay using recombinant desmogleins 1 and 3 for serodiagnosis of pemphigus

  1999cited by this paper
• The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile.

  1999cited by this paper
• Mechanisms of acantholysis in pemphigus vulgaris: role of IgG valence.

  1997cited by this paper
• HLA-DRB1*04 and DRB1*14 alleles are associated with susceptibility to pemphigus among Japanese.

  1997cited by this paper
• Influence of treatment on the clinical course of pemphigus vulgaris.

  1996cited by this paper
• Investigation into the catalytic role for the tryptophan residues within domain III of Pseudomonas aeruginosa exotoxin A.

  1996cited by this paper
• Investigation into the Catalytic Role for the Tryptophan Residues within Domain III of Pseudomonas aeruginosa Exotoxin A

  1996cited by this paper
• Conformational epitopes of pemphigus antigens (Dsg1 and Dsg3) are calcium dependent and glycosylation independent.

  1995cited by this paper
• Structural basis for major histocompatibility complex (MHC)-linked susceptibility to autoimmunity: charged residues of a single MHC binding pocket confer selective presentation of self-peptides in pemphigus vulgaris.

  1995cited by this paper
• The steroid-sparing effect of long-term plasmapheresis in pemphigus.

  1995cited by this paper
• HLA-DQA1, -DQB1 and -DRB1 genotyping in Japanese pemphigus vulgaris patients by the PCR-RFLP method.

  1994cited by this paper
• Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus.

  1994cited by this paper
• Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic.

  1992cited by this paper
• Recombinant toxins as novel therapeutic agents.

  1992cited by this paper
• Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris.

  1991cited by this paper
• Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies.

  1990cited by this paper
• Major histocompatibility complex haplotype studies in Ashkenazi Jewish patients with pemphigus vulgaris.

  1990cited by this paper
• Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity.

  1989cited by this paper
• A newly characterized HLA DQ beta allele associated with pemphigus vulgaris.

  1988cited by this paper
• Defining the role of complement in experimental pemphigus vulgaris in mice.

  1986cited by this paper
• Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease.

  1982cited by this paper
• Pemphigus: a 20-year review of 107 patients treated with corticosteroids.

  1976cited by this paper

• Chimeric antigen receptor (CAR) T-cell therapy in dermatology: A narrative review.

  2026cites this paper
• From technological iteration to clinical breakthrough: advances of CAR-T cell therapy in autoimmune diseases.

  2026cites this paper
• Case report: A rollercoaster journey of pemphigus vegetans

  2025cites this paper
• GENETIC AND MOLECULAR INSIGHTS INTO PEMPHIGUS VULGARIS WITH ORAL INVOLVEMENT: IMPLICATIONS FOR BIOLOGIC THERAPY

  2025cites this paper
• Antigen-Fc fusion therapy reduces severity of a model of pemphigus vulgaris without systemic immunosuppression.

  2025cites this paper
• Expanding the horizon of transient CAR T therapeutics using virus-free technology.

  2024cites this paper
• Pemphigus relapse: Mechanisms, risk factors, and agents associated with disease recurrence

  2024cites this paper
• Trends in disease severity and quality of life outcome measures in pemphigus clinical trials: A scoping review

  2024cites this paper
• Role of oral physician in the management of pemphigus vulgaris- A geriatric case report

  2023cites this paper
• Chimeric antigen receptor T cell and regulatory T cell therapy in non-oncology diseases: A narrative review of studies from 2017 to 2023

  2023cites this paper
• Diagnosis and Management of Bullous Disease.

  2023cites this paper
• Towards multiomic analysis of oral mucosal pathologies

  2023cites this paper
• Treatment of pemphigus beyond rituximab: chimeric autoantibody receptor T cell (CAAR-T cell) therapy

  2023cites this paper
• Apremilast prevents blistering in human epidermis and stabilizes keratinocyte adhesion in pemphigus

  2023cites this paper
• New advanced therapy medicinal products in treatment of autoimmune diseases

  2022cites this paper
• Apremilast prevents blistering in human epidermis by stabilization of keratinocyte adhesion in pemphigus

  2022cites this paper
• Immunotherapy for Pemphigus: Present and Future

  2022cites this paper
• Association of specific HLA alleles and haplotypes with pemphigus vulgaris in the Bulgarian population

  2022cites this paper
• Engineered antigen-specific regulatory T cells for autoimmune skin conditions.

  2021cites this paper
• Pênfigo vulgar em condição avançada na atenção básica: relato de caso

  2021cites this paper
• Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus.

  2021cites this paper
• B-cell targeted therapies in pemphigus

  2021cites this paper
• B-cell targeted therapies in pemphigus.

  2020cites this paper
• Oral management of pemphigus vulgaris in the intensive care unit.

  2020cites this paper
• The effects of immunostimulatory herbal supplements on autoimmune skin diseases.

  2020cites this paper
• Novel Therapies for Pemphigus Vulgaris

  2020cites this paper
• Immune serological diagnosis of pemphigus.

  2020cites this paper
• Modifications of the Transcriptomic Profile of Autoreactive B Cells From Pemphigus Patients After Treatment With Rituximab or a Standard Corticosteroid Regimen

  2019cites this paper
• Updates on diagnosis and management of autoimmune blistering diseases.

  2019cites this paper
• World Workshop of Oral Medicine VII: A systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus.

  2019cites this paper
• Treatment of pemphigus vulgaris: part 2 – emerging therapies

  2019cites this paper
• WWOM VII: A systematic review of immunobiologic therapy for oral manifestations of pemphigoid and pemphigus

  2019cites this paper
• Oral Vesicular and Bullous Lesions

  2019cites this paper
• What is novel in the clinical management of pemphigus

  2019cites this paper
• The anti-PLA2R antibody in membranous nephropathy: what we know and what remains a decade after its discovery.

  2019cites this paper
• Research Techniques Made Simple: CAR T-Cell Therapy.

  2018cites this paper
• Humoral Epitope Spreading in Autoimmune Bullous Diseases

  2018cites this paper
• Techniques Made Simple : CAR T-Cell Therapy

  2018cites this paper
• Focus on oral pemphigus vulgaris ’ s management

  2018cites this paper
• Manejo estomatológico y sistémico de pénfigo vulgar: reporte de un caso

  2018cites this paper
• Clinical Management of Oral Mucosal Disease: A Literature Review

  2018cites this paper
• Manifestation allgemeiner Hauterkrankungen in der Mundhöhle

  2017cites this paper